Biosynthetic And structural studies of a heavy chain disease protein

par Ein, Daniel, Buell, Donald N., Fahey, John L.
Publié 1969

SEPARATION OF HUMAN LYMPHOID CELLS INTO G(1), S, AND G(2) CELL CYCLE POPULATIONS BY USE OF A VELOCITY SEDIMENTATION TECHNIQUE

par Everson, Lloyd K., Buell, Donald N., Rogentine, G. Nicholas
Publié 1973

Insulin-Dependent Regulation of Insulin Receptor Concentrations: A Direct Demonstration in Cell Culture

par Gavin, James R., Roth, Jesse, Neville, David M., De Meyts, Pierre, Buell, Donald N.
Publié 1974

Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans

par Bekersky, Ihor, Fielding, Robert M., Dressler, Dawna E., Lee, Jean W., Buell, Donald N., Walsh, Thomas J.
Publié 2002

Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amp...

par Bekersky, Ihor, Fielding, Robert M., Dressler, Dawna E., Lee, Jean W., Buell, Donald N., Walsh, Thomas J.
Publié 2002

Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerat...

par Walsh, Thomas J., Goodman, Jesse L., Pappas, Peter, Bekersky, Ihor, Buell, Donald N., Roden, Maureen, Barrett, John, Anaissie, Elias J.
Publié 2001

Population Pharmacokinetics of Micafungin in Neonates and Young Infants

par Hope, William W., Smith, P. Brian, Arrieta, Antonio, Buell, Donald N., Roy, Michael, Kaibara, Atsunori, Walsh, Thomas J., Cohen-Wolkowiez, Michael, Benjamin, Daniel K.
Publié 2010

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

par Andes, David, Ambrose, Paul G., Hammel, Jeffrey P., Van Wart, Scott A., Iyer, Varsha, Reynolds, Daniel K., Buell, Donald N., Kovanda, Laura L., Bhavnani, Sujata M.
Publié 2011

Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

par Seibel, Nita L., Schwartz, Cindy, Arrieta, Antonio, Flynn, Patricia, Shad, Aziza, Albano, Edith, Keirns, James, Lau, Wendi M., Facklam, David P., Buell, Donald N., Walsh, Thomas J.
Publié 2005

Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates

par Smith, P Brian, Walsh, Thomas J, Hope, William, Arrieta, Antonio, Takada, Akitsugu, Kovanda, Laura L, Kearns, Gregory L, Kaufman, David, Sawamoto, T, Buell, Donald N, Benjamin, Daniel K
Publié 2009

Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

par Hope, William W., Seibel, Nita L., Schwartz, Cindy L., Arrieta, Antonio, Flynn, Patricia, Shad, Aziza, Albano, Edythe, Keirns, James J., Buell, Donald N., Gumbo, Tawanda, Drusano, George L., Walsh, Thomas J.
Publié 2007

Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants

par Benjamin, Daniel K, Smith, P Brian, Arrieta, Antonio, Castro, Lisa, Sánchez, Pablo J, Kaufman, David, Arnold, Leah J, Kovanda, Laura L, Sawamoto, Taiji, Buell, Donald N, Hope, William W, Walsh, Thomas J
Publié 2009

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis()

par Denning, David W., Marr, Kieren A., Lau, Wendi M., Facklam, David P., Ratanatharathorn, Voravit, Becker, Cornelia, Ullmann, Andrew J., Seibel, Nita L., Flynn, Patricia M., van Burik, Jo-Anne H., Buell, Donald N., Patterson, Thomas F.
Publié dans J Infect (2006)